QingSong Health Corporation announced that its board resolved on 22 June 2026 to activate the previously granted share-repurchase mandate, authorising the company to buy back shares worth up to HK$100 million on the open market.

The mandate, approved at the 22 May 2026 annual general meeting, permits repurchases of up to 10% of the company’s issued share capital, equivalent to a ceiling of 20.64 million shares based on the share count at that date. Purchases may take place from the date of the announcement until the conclusion of the next annual general meeting.

Funding will come from surplus cash on hand. In line with Hong Kong Listing Rules, each share may be repurchased at a price no more than 5% above the average closing price over the preceding five trading days. Acquired shares will be retained as treasury stock to support the 2026 Share Incentive Scheme.

The board stated that the initiative signals confidence in the company’s outlook and will be monitored regularly, with potential adjustments to scope or timing depending on market conditions. Implementation remains at the board’s discretion, and the company cautioned investors that there is no assurance on the timing, volume, or execution of repurchases.